{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:35:10Z","timestamp":1787495710762,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.pcad.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T02:25:09Z","timestamp":1629426309000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization"],"prefix":"10.1016","volume":"69","author":[{"given":"Ram D.","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Preston","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pcad.2021.08.003_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.pcad.2021.08.003_bb0010","first-page":"1678","article-title":"Cardiovascular risk reduction with icosapent ethyl","volume":"380","author":"Bhatt","year":"2019","journal-title":"Reply N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2021.08.003_bb0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl\u2013intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"issue":"15","key":"10.1016\/j.pcad.2021.08.003_bb0020","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehz179","article-title":"REDUCE-IT: residual cardiovascular risk in statin-treated patients with elevated triglycerides: now we can REDUCE-IT!","volume":"40","author":"Bhatt","year":"2019","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.pcad.2021.08.003_bb0025","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.08.003_bb0030","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.pcad.2021.08.003_bb0035","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2019.08.007","article-title":"Reply: ischemic event reduction and triglycerides","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2021.08.003_bb0040","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ehjcvp\/pvaa118","article-title":"REDUCE-IT Investigators. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results","volume":"7","author":"Olshansky","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"10.1016\/j.pcad.2021.08.003_bb0045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3,146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2021.08.003_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT REVASC","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2021.08.003_bb0055","series-title":"Presented at: Transcatheter Cardiovascular Therapeutics (TCT) CONNECT-3","article-title":"Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI","author":"Peterson","year":"2020"},{"key":"10.1016\/j.pcad.2021.08.003_bb0060","series-title":"Presented at: The American Heart Association Scientific Sessions","article-title":"Icosapent ethyl reduces ischemic events in patients with prior coronary artery bypass grafting: REDUCE-IT CABG","author":"Verma","year":"2020"},{"issue":"9583","key":"10.1016\/j.pcad.2021.08.003_bb0065","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(07)61114-3","volume":"370","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pcad.2021.08.003_bb0070","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2021.08.003_bb0075","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/cvr\/cvaa184","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results","volume":"117","author":"Budoff","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"40","key":"10.1016\/j.pcad.2021.08.003_bb0080","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2021.08.003_bb0085","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2021.08.003_bb0090","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2021.08.003_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chemphyslip.2018.01.002","article-title":"Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction","volume":"212","author":"Sherratt","year":"2018","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.pcad.2021.08.003_bb0100","doi-asserted-by":"crossref","first-page":"J1","DOI":"10.1093\/eurheartj\/suaa114","article-title":"Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside","volume":"22","author":"Bhatt","year":"2020","journal-title":"Eur Heart J Suppl"},{"issue":"1","key":"10.1016\/j.pcad.2021.08.003_bb0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.pcad.2021.08.003_bb0110","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/00325481.2017.1385365","article-title":"Can pleiotropic effects of EPA impact residual cardiovascular risk?","volume":"129","author":"Nelson","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.pcad.2021.08.003_bb0115","first-page":"502","article-title":"Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism","volume":"2015","author":"Mason","year":"1848","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pcad.2021.08.003_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","article-title":"Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents","volume":"68","author":"Mason","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pcad.2021.08.003_bb0125","first-page":"3131","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"2016","author":"Mason","year":"1858","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pcad.2021.08.003_bb0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2018.01.062","article-title":"Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid","volume":"496","author":"Sherratt","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pcad.2021.08.003_bb0135","first-page":"173","article-title":"Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability","author":"Sherratt","year":"2021","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids"},{"key":"10.1016\/j.pcad.2021.08.003_bb0140","first-page":"1","article-title":"New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease","volume":"21","author":"Mason","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.pcad.2021.08.003_bb0145","first-page":"183254","article-title":"Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro","volume":"2020","author":"Sherratt","year":"1862","journal-title":"Biochim Biophys Acta Biomembranes"},{"key":"10.1016\/j.pcad.2021.08.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2021.03.014","article-title":"Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction","author":"Mason","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2021.08.003_bb0155","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.bpj.2021.04.009","article-title":"EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol","volume":"120","author":"Jacobs","year":"2021","journal-title":"Biophys J"},{"key":"10.1016\/j.pcad.2021.08.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100106","article-title":"Eicosapentaenoic acid and docosahexaenoic acid containing phospholipids have contrasting effects on membrane structure","author":"Sherratt","year":"2021","journal-title":"J Lipid Res"},{"issue":"18","key":"10.1016\/j.pcad.2021.08.003_bb0165","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jacc.2020.09.005","article-title":"A revolution in omega-3 fatty acid research","volume":"76","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.pcad.2021.08.003_bb0170","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.2021.0824","article-title":"Omega-3 fatty acids effect on major cardiovascular events in patients at high cardiovascular risk","volume":"325","author":"Olshansky","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pcad.2021.08.003_bb0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMe1814004","article-title":"FISHing for the miracle of eicosapentaenoic acid","volume":"380","author":"Kastelein","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.pcad.2021.08.003_bb0180","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/eurheartj\/ehz778","article-title":"Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics","volume":"41","author":"Boden","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2021.08.003_bb0185","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/01.CIR.85.3.950","article-title":"Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty","volume":"85","author":"Bairati","year":"1992","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pcad.2021.08.003_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.mayocp.2020.08.034","article-title":"Effect of Omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials","volume":"96","author":"Bernasconi","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2021.08.003_bb0195","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"100997","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.pcad.2021.08.003_bb0200","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease","volume":"73","author":"Picard","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2021.08.003_bb0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pcad.2021.08.003_bb0210","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/clc.23437","article-title":"Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?","volume":"43","author":"Ferri\u00e8res","year":"2020","journal-title":"Clin Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2021.08.003_bb0215","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/HCO.0000000000000800","article-title":"Generalizability of reduction of cardiovascular events with icosapent ethyl-intervention trial in patients with a history of coronary artery bypass graft surgery","volume":"36","author":"Kosmopoulos","year":"2021","journal-title":"Curr Opin Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2021.08.003_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11892-020-01343-7","article-title":"The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction","volume":"20","author":"Wang","year":"2020","journal-title":"Curr Diab Rep"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062021000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062021000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:19:01Z","timestamp":1758500341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062021000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":44,"alternative-id":["S0033062021000955"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2021.08.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740717061.793589639","asserted-by":"object"}]},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}